AXT 1003
Alternative Names: AXT-1003Latest Information Update: 11 Oct 2024
Price :
$50 *
At a glance
- Originator Novartis
- Developer Axter Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma; Solid tumours
- Preclinical Prostate cancer
Most Recent Events
- 04 Sep 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (PO) (NCT06484985)
- 16 Jul 2024 Axter Therapeutics plans to initiate a phase I trial for Non-Hodgkin Lymphoma (Second-line therapy or greater) and Solid tumours (Late-stage disease, Metastatic disease) in China (PO) (NCT06484985)
- 22 Feb 2024 Preclinical trials in Prostate cancer in China (PO) (Axter Therapeutics pipeline, February 2024)